miR-92在上皮性卵巢癌组织中的表达及临床意义
|
摘要
目的探讨mi R-92在上皮性卵巢癌组织中的表达及临床意义。方法选取2007年1月～2017年12月我院收治的300例各期上皮性卵巢癌患者、300例上皮性卵巢良性肿瘤患者以及300例因生殖器官(除卵巢外)良性病变而行单侧或双侧卵巢切除患者作为研究对象,采用实时荧光定量检测法检测三组患者术后卵巢癌癌组织、卵巢良性肿瘤组织及正常卵巢组织中mi R-92的表达水平。结果卵巢癌组患者的mi R-92水平高于卵巢良性肿瘤组及正常卵巢组,差异有统计学意义(P<0.05)。卵巢癌组的mi R-92水平与淋巴结转移、临床分期以及肿瘤分化程度有关(P<0.05)。结论 mi R-92表达水平可作为上皮性卵巢癌的临床诊断依据。
Objective To investigate the expression and clinical significance of miR-92 in epithelial ovarian cancer.Methods From January 2007 to December 2017, altogether 300 cases of patients with epithelial ovarian cancer, 300 cases of benign ovarian tumor, and 300 patients who underwent unilateral or bilateral ovariectomy because of benign lesions of reproductive organs(except ovary) were selected as the research objects. The real-time fluorescence quantitative assay was used to detect the expression of miR-92 in ovarian cancer, benign ovarian tumor and normal ovarian tissues. Results The level of miR-92 in ovarian cancer group was higher than that in ovarian benign tumor group and normal ovarian group, and the difference was statistically significant(P<0.05). The level of miR-92 in ovarian cancer group was related to lymph node metastasis, clinical stage and tumor differentiation(P<0.05). Conclusion The level of miR-92 expression can be used as a clinical basis for the diagnosis of epithelial ovarian cancer.
Objective To investigate the expression and clinical significance of miR-92 in epithelial ovarian cancer.Methods From January 2007 to December 2017, altogether 300 cases of patients with epithelial ovarian cancer, 300 cases of benign ovarian tumor, and 300 patients who underwent unilateral or bilateral ovariectomy because of benign lesions of reproductive organs(except ovary) were selected as the research objects. The real-time fluorescence quantitative assay was used to detect the expression of miR-92 in ovarian cancer, benign ovarian tumor and normal ovarian tissues. Results The level of miR-92 in ovarian cancer group was higher than that in ovarian benign tumor group and normal ovarian group, and the difference was statistically significant(P<0.05). The level of miR-92 in ovarian cancer group was related to lymph node metastasis, clinical stage and tumor differentiation(P<0.05). Conclusion The level of miR-92 expression can be used as a clinical basis for the diagnosis of epithelial ovarian cancer.
引文
[1]马晶晶,吴姗,石莉,等.miR-218在上皮性卵巢癌中的表达及其临床意义[J].现代妇产科进展,2014,23(2):98-101.
[2]郭凤军,邹颖刚,范丽梅,等.微小RNA-92在上皮性卵巢癌患者血清中的筛查[J].中国实验诊断学,2015,19(9):1478-1480.
[3]张申华,朱小晖.mi R-212在上皮性卵巢癌中表达的临床意义[J].现代肿瘤医学,2016,24(17):2785-2788.
[4]黄群,王莉,王红英.人肺腺癌转移相关转录本1基因在上皮性卵巢癌中的表达及其临床意义[J].肿瘤研究与临床,2015,27(11):745-747.
[5]王丹丹,王敏,双婷,等.mi R-134 miR-17~92基因簇与卵巢癌耐药的关系[J].中国实用妇科与产科杂志,2014,30(2):118-122.
[6]李伟宏.MicroRNA-200b在卵巢癌组织及血浆中的表达及其对癌细胞侵袭迁移的影响[J].中国现代医学杂志,2016,26(20):40-43.
[7]于晓敏,宋克娟,吕腾,等.上皮性卵巢癌患者血清microRNA-21的水平及其临床意义研究[J].现代生物医学进展,2015,15(6):1050-1053.
[8]朱滔,张平,郑伟.卵巢癌血清相关mi RNAs的筛选及其临床意义[J].中国癌症杂志,2016,26(3):201-207.
[9]张彭南,孙红,蒋红元.miR-483-5p在上皮性卵巢癌中的表达及其对顺铂敏感性的影响[J].中国癌症杂志,2016,26(5):394-398.
[10]彭靓,叶萍,陈国庆,等.Ⅱ~Ⅲ期上皮性卵巢癌原发灶及转移灶中mi R-199a-5p表达变化及其意义[J].山东医药,2017,57(35):39-41.
[11]眭蕊,米雪,苗劲蔚.mi R-214、mi R-503在上皮性卵巢癌组织及血清外泌小体中表达的研究[J].癌症进展,2017,15(2):128-131.
[12]李励,冯浩,刘胜楠,等.mi R-26b在卵巢癌组织中的表达水平及其与预后的关系[J].临床和实验医学杂志,2017,16(17):1700-1703.
[13]崔开颖,赵素芬,朱根海.上皮性卵巢癌组织中miR-21-5p、mi R-29-3p、mi R-139-5p表达变化及意义[J].山东医药,2017,57(22):65-67.
[14]徐志宏,吴小华,姚铁柱,等.mir-99a的表达与上皮性卵巢癌患者预后的关系[J].山东大学学报(医学版),2016,54(3):77-80.
[15]接智慧,吴建磊,王敏.mi R-17~92基因簇过表达调控PTEN、BIM蛋白对卵巢癌SKOV3细胞紫杉醇耐药的影响[J].现代妇产科进展,2016,25(7):507-510.
[2]郭凤军,邹颖刚,范丽梅,等.微小RNA-92在上皮性卵巢癌患者血清中的筛查[J].中国实验诊断学,2015,19(9):1478-1480.
[3]张申华,朱小晖.mi R-212在上皮性卵巢癌中表达的临床意义[J].现代肿瘤医学,2016,24(17):2785-2788.
[4]黄群,王莉,王红英.人肺腺癌转移相关转录本1基因在上皮性卵巢癌中的表达及其临床意义[J].肿瘤研究与临床,2015,27(11):745-747.
[5]王丹丹,王敏,双婷,等.mi R-134 miR-17~92基因簇与卵巢癌耐药的关系[J].中国实用妇科与产科杂志,2014,30(2):118-122.
[6]李伟宏.MicroRNA-200b在卵巢癌组织及血浆中的表达及其对癌细胞侵袭迁移的影响[J].中国现代医学杂志,2016,26(20):40-43.
[7]于晓敏,宋克娟,吕腾,等.上皮性卵巢癌患者血清microRNA-21的水平及其临床意义研究[J].现代生物医学进展,2015,15(6):1050-1053.
[8]朱滔,张平,郑伟.卵巢癌血清相关mi RNAs的筛选及其临床意义[J].中国癌症杂志,2016,26(3):201-207.
[9]张彭南,孙红,蒋红元.miR-483-5p在上皮性卵巢癌中的表达及其对顺铂敏感性的影响[J].中国癌症杂志,2016,26(5):394-398.
[10]彭靓,叶萍,陈国庆,等.Ⅱ~Ⅲ期上皮性卵巢癌原发灶及转移灶中mi R-199a-5p表达变化及其意义[J].山东医药,2017,57(35):39-41.
[11]眭蕊,米雪,苗劲蔚.mi R-214、mi R-503在上皮性卵巢癌组织及血清外泌小体中表达的研究[J].癌症进展,2017,15(2):128-131.
[12]李励,冯浩,刘胜楠,等.mi R-26b在卵巢癌组织中的表达水平及其与预后的关系[J].临床和实验医学杂志,2017,16(17):1700-1703.
[13]崔开颖,赵素芬,朱根海.上皮性卵巢癌组织中miR-21-5p、mi R-29-3p、mi R-139-5p表达变化及意义[J].山东医药,2017,57(22):65-67.
[14]徐志宏,吴小华,姚铁柱,等.mir-99a的表达与上皮性卵巢癌患者预后的关系[J].山东大学学报(医学版),2016,54(3):77-80.
[15]接智慧,吴建磊,王敏.mi R-17~92基因簇过表达调控PTEN、BIM蛋白对卵巢癌SKOV3细胞紫杉醇耐药的影响[J].现代妇产科进展,2016,25(7):507-510.